Licaminlimab Phase 2 Dry Eye Disease Study
Summary
A Phase 2 clinical trial (NCT07548632) evaluating the efficacy and safety of topical ophthalmic licaminlimab versus vehicle in participants with Dry Eye Disease and a specific genotype has been registered on ClinicalTrials.gov. The study includes an Artificial Tear Run-in period and will test licaminlimab against a vehicle placebo. The trial is categorized as Phase 2 and was posted on April 23, 2026.
“The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of licaminlimab as compared to vehicle in participants with Dry Eye Disease and a specific genotype.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
A new Phase 2 clinical trial has been registered on ClinicalTrials.gov under NCT07548632, studying licaminlimab administered topically ophthalmically for Dry Eye Disease. The trial will compare licaminlimab against a vehicle placebo in participants with a specific genotype, with an Artificial Tear Run-in period included in the study design.
Pharmaceutical sponsors and clinical research organizations conducting ophthalmic drug trials should note this Phase 2 registration as it represents an active clinical development program for licaminlimab in an ocular indication. Study outcomes may inform future regulatory submissions for this candidate.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Clinical Study Evaluating Licaminlimab for Dry Eye Disease
Phase 2 NCT07548632 Kind: PHASE2 Apr 23, 2026
Abstract
The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of licaminlimab as compared to vehicle in participants with Dry Eye Disease and a specific genotype.
Conditions: Dry Eye Disease (DED)
Interventions: Artificial Tear Run-in, licaminlimab, Vehicle of licaminlimab
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.